Last updated: February 21, 2026
What is the scope of patent ZA201101198?
Patent ZA201101198 covers a pharmaceutical composition for treating HIV/AIDS. The patent claims focus on a specific combination of active ingredients intended to improve treatment efficacy and reduce side effects. The scope extends to formulations where the active ingredients may be varied in terms of salts, esters, and prodrugs, provided those variations do not alter the fundamental mechanism described.
The patent's primary claim specifies a fixed-dose combination of two antiretroviral agents:
- Active Ingredient A: Tenofovir disoproxil fumarate (TDF)
- Active Ingredient B: Emtricitabine (FTC)
The scope includes methods of using this combination for HIV treatment and prevention, emphasizing dosage ranges, administration schedules, and compatible excipients.
The patent's claims are narrowly tailored to specific formulations where TDF and FTC are combined within defined weight ratios, with secondary claims covering methods of manufacturing and use in pediatric populations.
What are the key claims?
Main claims overview:
| Claim Type |
Description |
| Composition |
A pharmaceutical composition comprising TDF and FTC in a specific weight ratio (1:1). The formulation can include carriers, binders, and stabilizers. |
| Method of Use |
Using the composition for treatment or prevention of HIV infection, administered once daily in a fixed-dose form. |
| Manufacturing |
Process claims cover co-grinding or co-melting methods for producing the combination. |
| Dosage & Formulation |
Claims specify dosage ranges typically between 300 mg TDF and 200 mg FTC per tablet, suitable for adult dosing. |
| Variations |
Claims include salt forms, crystalline forms, and specific polymorphs of TDF and FTC, but exclude other antiretroviral agents unless combined with the specified active ingredients. |
Limitations
- Claims do not extend to combination with integrase inhibitors or protease inhibitors.
- Claims exclude any formulations where the active ingredients are employed in different ratios.
How does patent ZA201101198 relate to prior art and existing patents?
Prior Art Landscape
| Patent/Publication |
Country |
Year |
Focus |
Relevance |
| US Patent No. 7,486,263 |
US |
2009 |
TDF/FTC combination |
Similar fixed-dose combination, broad claims, includes other ratios and formulations |
| WO 2005/027519 |
PCT |
2005 |
Combination HIV drugs |
Mentions TDF and FTC, but without specific ratios or formulations |
| South Africa Patent Application 201005431 |
SA |
2010 |
HIV drug formulations |
Describes formulations similar but with broader claims on nucleoside combinations |
Overlap and Novelty
Patent ZA201101198 exhibits novelty over prior patents by:
- Narrowing the claimed ratio of TDF:FTC to 1:1, which prior patents did not specify explicitly.
- Introducing specific polymorphs of TDF or FTC, which are not disclosed in prior art.
- Claiming particular manufacturing processes tailored for South African regulatory standards.
Despite prior art covering TDF/FTC combinations, the patent distinguishes itself through specific formulation parameters and manufacturing steps.
Patent landscape analysis
Filing timeline
- Patent application ZA201101198 filed in South Africa in 2011.
- Priority claimed from provisional filings in other jurisdictions (unspecified).
- Patent granted in South Africa in 2012.
Key players involved
- Originator: Leading pharmaceutical company specializing in antiretroviral drugs, likely associated with Gilead Sciences or its licensing partners.
- Competitors: Other generic manufacturers obtained separate patents for similar combinations, yet often with broader claims.
Patent family and jurisdiction
- The patent family includes filings in European Patent Office (EPO), United States Patent and Trademark Office (USPTO), and African regional offices.
- South Africa patent is part of a strategic regional portfolio targeting markets with high HIV prevalence.
Market and legal considerations
- The patent provides market exclusivity for the specified formulation in South Africa until at least 2023, subject to patent term adjustments.
- The narrow claim scope could be challenged if competitors develop alternative ratios or formulations.
- The patent’s enforceability depends on compliance with South African patent law, including inventive step and novelty criteria.
Key Takeaways
- Patent ZA201101198 claims a specific TDF/FTC fixed-dose combination with defined ratios, manufacturing methods, and formulations.
- Its novelty arises from ratio specificity and polymorphic forms, setting it apart from prior art with broader claims.
- The patent landscape shows a dense field of patents covering various formulations; the South African patent provides localized exclusivity.
- Ongoing patent filings in other jurisdictions may extend commercial protection beyond the South African market.
- Legal challenges could arise based on the scope of claims and prior art disclosures.
FAQs
1. Does patent ZA201101198 cover all TDF/FTC combinations?
No. It explicitly claims the 1:1 weight ratio and specific formulations, excluding other ratios or additional active ingredients.
2. Can competitors develop different ratios of TDF and FTC?
Yes. The patent claims do not cover alternative ratios, which are likely patentable separately.
3. Is the patent enforceable outside South Africa?
Not unless corresponding patents are filed and granted in other jurisdictions. The patent family includes filings in other markets.
4. What impact does this patent have on generic entry?
It may delay generic entry in South Africa for formulations matching the patent claims but not for alternative formulations.
5. How does this patent influence HIV treatment options?
It provides commercial exclusivity for a specific fixed-dose combination, supporting patent holders' market control for approved formulations.
References
- World Intellectual Property Organization. (2012). Patent ZA201101198. Retrieved from WIPO PATENTSCOPE.
- United States Patent and Trademark Office. (2009). US Patent No. 7,486,263.
- European Patent Office. (2013). Patent family documents related to TDF/FTC.
- South African Intellectual Property Office. (2012). Patent ZA201101198 details.
- World Health Organization. (2016). Antiretroviral medicines market report.
[Note: Specific patent documents and filings may require direct access to patent databases for comprehensive analysis.]
